159 related articles for article (PubMed ID: 34146539)
1. Structure based design, synthesis, and evaluation of anti-CML activity of the quinolinequinones as LY83583 analogs.
Bayrak N; Ciftci HI; Yıldız M; Yıldırım H; Sever B; Tateishi H; Otsuka M; Fujita M; Tuyun AF
Chem Biol Interact; 2021 Aug; 345():109555. PubMed ID: 34146539
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and investigation of the mechanism of action underlying anti-leukemic effects of the quinolinequinones as LY83583 analogs.
Ciftci HI; Bayrak N; Yıldız M; Yıldırım H; Sever B; Tateishi H; Otsuka M; Fujita M; Tuyun AF
Bioorg Chem; 2021 Sep; 114():105160. PubMed ID: 34328861
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological activity of Plastoquinone analogs as a new class of anticancer agents.
Bayrak N; Yıldırım H; Yıldız M; Radwan MO; Otsuka M; Fujita M; Tuyun AF; Ciftci HI
Bioorg Chem; 2019 Nov; 92():103255. PubMed ID: 31542717
[TBL] [Abstract][Full Text] [Related]
4. A New Series of Antileukemic Agents: Design, Synthesis, In Vitro and In Silico Evaluation of Thiazole-Based ABL1 Kinase Inhibitors.
Zeytün E; Altıntop MD; Sever B; Özdemir A; Ellakwa DE; Ocak Z; Ciftci HI; Otsuka M; Fujita M; Radwan MO
Anticancer Agents Med Chem; 2021; 21(9):1099-1109. PubMed ID: 32838725
[TBL] [Abstract][Full Text] [Related]
5. A novel series of chlorinated plastoquinone analogs: Design, synthesis, and evaluation of anticancer activity.
Bayrak N; Yıldırım H; Yıldız M; Radwan MO; Otsuka M; Fujita M; Ciftci HI; Tuyun AF
Chem Biol Drug Des; 2020 Mar; 95(3):343-354. PubMed ID: 31785034
[TBL] [Abstract][Full Text] [Related]
6. Discovery and structure-activity relationship of plastoquinone analogs as anticancer agents against chronic myelogenous leukemia cells.
Ciftci HI; Bayrak N; Yıldırım H; Yıldız M; Radwan MO; Otsuka M; Fujita M; Tuyun AF
Arch Pharm (Weinheim); 2019 Dec; 352(12):e1900170. PubMed ID: 31602720
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
El-Damasy AK; Jin H; Seo SH; Bang EK; Keum G
Eur J Med Chem; 2020 Dec; 207():112710. PubMed ID: 32961435
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
9. Molecular Docking, G-QSAR Studies, Synthesis and Anticancer Screening of Some New 2-Phenazinamines as Bcr-Abl Tyrosine Kinase Inhibitors.
Kale MA; Sonwane GM
Curr Drug Discov Technol; 2020; 17(2):213-224. PubMed ID: 30210004
[TBL] [Abstract][Full Text] [Related]
10. Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML).
Liu F; Wang B; Wang Q; Qi Z; Chen C; Kong LL; Chen JY; Liu X; Wang A; Hu C; Wang W; Wang H; Wu F; Ruan Y; Qi S; Liu J; Zou F; Hu Z; Wang W; Wang L; Zhang S; Yun CH; Zhai Z; Liu J; Liu Q
Oncotarget; 2016 Jul; 7(29):45562-45574. PubMed ID: 27322145
[TBL] [Abstract][Full Text] [Related]
11. Determination of the Apoptotic Effect and Molecular Docking of Benzamide Derivative XT5 in K562 Cells.
Ozkan T; Hekmatshoar Y; Ertan-Bolelli T; Hidayat AN; Beksac M; Aki-Yalcin E; Yalcin I; Sunguroglu A
Anticancer Agents Med Chem; 2018; 18(11):1521-1530. PubMed ID: 29298654
[TBL] [Abstract][Full Text] [Related]
12. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
13. In Vitro and In Silico Study of Analogs of Plant Product Plastoquinone to Be Effective in Colorectal Cancer Treatment.
Ciftci H; Sever B; Ocak F; Bayrak N; Yıldız M; Yıldırım H; DeMirci H; Tateishi H; Otsuka M; Fujita M; TuYuN AF
Molecules; 2022 Jan; 27(3):. PubMed ID: 35163957
[TBL] [Abstract][Full Text] [Related]
14. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Quinolinequinone Analogs with Promising Cytotoxic Activity against Breast Cancer.
Yilmaz Goler AM; Tarbin Jannuzzi A; Biswas A; Mondal S; Basavanakatti VN; Jayaprakash Venkatesan R; Yıldırım H; Yıldız M; Çelik Onar H; Bayrak N; Jayaprakash V; TuYuN AF
Chem Biodivers; 2023 Sep; 20(9):e202300848. PubMed ID: 37590495
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Evaluation of 2-Naphthaleno trans-Stilbenes and Cyanostilbenes as Anticancer Agents.
Madadi NR; Penthala NR; Ketkar A; Eoff RL; Trujullo-Alonso V; Guzman ML; Crooks PA
Anticancer Agents Med Chem; 2018; 18(4):556-564. PubMed ID: 28403783
[TBL] [Abstract][Full Text] [Related]
17. Andrographolide and its potent derivative exhibit anticancer effects against imatinib-resistant chronic myeloid leukemia cells by downregulating the Bcr-Abl oncoprotein.
Liao HC; Chou YJ; Lin CC; Liu SH; Oswita A; Huang YL; Wang YL; Syu JL; Sun CM; Leu CM; Lin CH; Fu SL
Biochem Pharmacol; 2019 May; 163():308-320. PubMed ID: 30822403
[TBL] [Abstract][Full Text] [Related]
18. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Anticancer Effects of Two New Potent Hydrazide Compounds on Leukemic Cells.
Tavakolfar S; Mousavi E; Almasirad A; Amanzadeh A; Atyabi SM; Yaghamii P; Samiee-Sadr S; Salimi M
Anticancer Agents Med Chem; 2016; 16(12):1646-1651. PubMed ID: 27039920
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis and Biological Evaluation of Pentacyclic Triterpene Derivatives: Optimization of Anti-ABL Kinase Activity.
I Ciftci H; O Radwan M; E Ozturk S; Ulusoy NG; Sozer E; E Ellakwa D; Ocak Z; Can M; F S Ali T; I Abd-Alla H; Yayli N; Tateishi H; Otsuka M; Fujita M
Molecules; 2019 Sep; 24(19):. PubMed ID: 31574910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
